ROIV241220P16000
- 0.00
- 0.000.00%
Roivant Sciences Newsroom
Vertex Leads J.P. Morgan's Top Biotech Picks List for 2025
JPMorgan Updates Its U.S. Analyst Focus List – Adds TPR, ALRM, REG
JPMorgan's 'Analyst Focus List' – Growth, Income, Value, Short Ideas
Roivant Sciences' (NASDAQ:ROIV) Shareholders Should Assess Earnings With Caution
Vivek Ramaswamy's Marching Orders: Cut Trillions for Trump -- WSJ
The Analyst Landscape: 5 Takes On Roivant Sciences
Roivant Sciences Analyst Ratings
Trump Taps Musk, Ramaswamy to Lead a 'Department of Government Efficiency.' He Called It 'The Manhattan Project of Our Time.' -- Barrons.com
Unusual Options Activity: GAP, SQ and Others Attract Market Bets, GAP V/OI Ratio Reaches 468.8
EST Nov 13th Morning Delivery - In the last two hours of trading, 10 options with a high V/OI ratio were detected. With the market volatile, it's crucial to stay informed on the latest options trends.
H.C. Wainwright Maintains Roivant Sciences(ROIV.US) With Buy Rating, Maintains Target Price $18
Analyst Recommends Buy on Roivant Sciences Amid Promising Developments of Brepocitinib
Roivant Sciences Ltd. (ROIV) Q2 2024 Earnings Call Transcript Summary
Roivant Sciences Ltd. (ROIV) Q2 2024 Earnings Call Transcript
10-Q: Q2 2025 Earnings Report
8-K: Roivant Reports Financial Results for the Second Quarter Ended September 30, 2024, and Provides Business Update
Roivant Sciences 2Q Rev $4.47M >ROIV
Earnings Flash (ROIV) ROIVANT SCIENCES Reports Q2 Revenue $4.5M
Stocks Down Pre-Bell After Record Highs as Earnings Season Wanes; Asia, Europe Fall
Express News | Roivant Sciences Q2 Operating Expenses USD 346.188 Million
Express News | Roivant Sciences Q2 EPS USD -0.31